Trial · NCT02971605
Persisting Effects of Psilocybin
NCT02971605, Phase 1, Phase 2, Completed, Johns Hopkins University; results first posted 2019-09-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Persisting Effects of Psilocybin. Trials, record NCT02971605. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02971605
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Persisting Effects of Psilocybin
- NCT number
- NCT02971605
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 13 participants, actual
- Lead sponsor
- Johns Hopkins University
- Conditions
- Healthy
- Interventions
- Psilocybin
- First posted
- 2016-11-23
- Last updated
- 2019-09-10
- Results first posted
- 2019-09-10
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Amygdala Response to Stimuli in the Emotion Recognition Test | 1 day pre (baseline), 1 week post, and 1 month post session | Blood oxygenation level-dependent (BOLD) percent signal change in response to stimuli in the emotion recognition task was measured in the left and right amygdala. |
| Secondary | Change in Longitudinal Emotion and Mood Questionnaire Scores | 1 day pre (baseline), 1 week post, and 1 month post session | Participants were assessed on a variety of questionnaires that probed emotional functioning and mood state. Higher scores on each subscale are indicative of higher levels of each emotion/mood (e.g., low score on Depression (POMS) indicates low level of depressed mood). Depression Anxiety Stress Scale (DASS): Range 0-56 on all subscales Dispositional Positive Emotion Scale (DPES): Range 1-7 on all subscales Positive \& Negative Affect Schedule Expanded (PANAS-X): Range 0-50 on all subscales Profile of Mood States (POMS): Ranges vary by subscale. Tension (0-36); Depression (0-60); Anger (0-48); Fatigue (0-28); Confusion (0-28); Vigor (0-36); Mood Disturbance (-36-168) State Trait Anxiety Inventory (STAI): Range 20-80 on all subscales Tellegen Absorption Scale (TAS): Range 0-34 Big Five Inventory (BFI): Range 1-5 on all subscales |
| Secondary | Change in Emotional Functioning Task Accuracy | 1 day pre (baseline), 1 week post, and 1 month post session | These tasks measure emotional responding that may be altered by psilocybin. Emotional discrimination task: participants were presented with images of emotional facial expressions or shapes (control), and were instructed to discriminate between the images. Emotion recognition task: participants were presented images of actors and were asked to identify the emotional facial expression (happy, sad, fear, angry, neutral) of each actor. Emotional conflict Stroop task: participants were shown emotional facial expressions (targets) with emotional words overlain (distractors) and were asked to identify the valence of the facial expression, either positive or negative. |
| Secondary | Change in Emotional Functioning Tasks Response Time (Milliseconds) | 1-day pre (baseline), 1-week post, 1-month post session | These tasks measure emotional responding that may be altered by psilocybin. Emotional discrimination task: participants were presented with images of emotional facial expressions or shapes (control), and were instructed to discriminate between the images. Emotion recognition task: participants were presented images of actors and were asked to identify the emotional facial expression (happy, sad, fear, angry, neutral) of each actor. Emotional conflict Stroop task: participants were shown emotional facial expressions (targets) with emotional words overlain (distractors) and were asked to identify the valence of the facial expression, either positive or negative. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Amygdala Response to Stimuli in the Emotion Recognition Test | 1 day pre (baseline), 1 week post, and 1 month post session | BOLD percent signal change | MEAN | |
| SECONDARY | Change in Longitudinal Emotion and Mood Questionnaire Scores | 1 day pre (baseline), 1 week post, and 1 month post session | The Big Five Inventory (BFI) and the Tellegen Absorption Scale (TAS) were not administered at 1-week post, and were only administered at Baseline and 1-month post. | score on a scale | MEAN |
| SECONDARY | Change in Emotional Functioning Task Accuracy | 1 day pre (baseline), 1 week post, and 1 month post session | percentage of correct responses | MEAN | |
| SECONDARY | Change in Emotional Functioning Tasks Response Time (Milliseconds) | 1-day pre (baseline), 1-week post, 1-month post session | milliseconds | MEAN |
Source ClinicalTrials.gov
Results by group159
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Amygdala Response to Stimuli in the Emotion Recognition Test | Baseline | L Amygdala contrast: Happy | 0.835 | Standard Error 0.342 | BOLD percent signal change |
| Amygdala Response to Stimuli in the Emotion Recognition Test | 1-week Post Session | L Amygdala contrast: Happy | -0.759 | Standard Error 0.63 | BOLD percent signal change |
| Amygdala Response to Stimuli in the Emotion Recognition Test | 1-month Post Session | L Amygdala contrast: Happy | 0.619 | Standard Error 0.449 | BOLD percent signal change |
| Amygdala Response to Stimuli in the Emotion Recognition Test | Baseline | L Amygdala contrast: Sad | 0.503 | Standard Error 0.403 | BOLD percent signal change |
| Amygdala Response to Stimuli in the Emotion Recognition Test | 1-week Post Session | L Amygdala contrast: Sad | -0.514 | Standard Error 0.635 | BOLD percent signal change |
| Amygdala Response to Stimuli in the Emotion Recognition Test | 1-month Post Session | L Amygdala contrast: Sad | 0.999 | Standard Error 0.563 | BOLD percent signal change |
| Amygdala Response to Stimuli in the Emotion Recognition Test | Baseline | L Amygdala contrast: Fearful | 0.525 | Standard Error 0.421 | BOLD percent signal change |
| Amygdala Response to Stimuli in the Emotion Recognition Test | 1-week Post Session | L Amygdala contrast: Fearful | -0.928 | Standard Error 0.696 | BOLD percent signal change |
| Amygdala Response to Stimuli in the Emotion Recognition Test | 1-month Post Session | L Amygdala contrast: Fearful | 0.664 | Standard Error 0.584 | BOLD percent signal change |
| Amygdala Response to Stimuli in the Emotion Recognition Test | Baseline | L Amygdala contrast: Angry | 0.514 | Standard Error 0.357 | BOLD percent signal change |
1 to 10 of 159Source ClinicalTrials.gov
See all 159 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Psilocybin | 13 | |
| Overall Study | COMPLETED | Psilocybin | 12 | |
| Overall Study | NOT COMPLETED | Psilocybin | 1 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Cardiac event | Cardiac disorders | Psilocybin | 2 | 13 | 2 |
| other | Thyroid hormone changes | Endocrine disorders | Psilocybin | 1 | 13 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Psilocybin | 0 | 13 |
| Total, other adverse events | Psilocybin | 3 | 13 |
| Total, serious adverse events | Psilocybin | 0 | 13 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R03DA042336 | Measurement of persisting changes in emotional brain functioning produced by psilocybin | BARRETT, FREDERICK STREETER | JOHNS HOPKINS UNIVERSITY | NATIONAL INSTITUTE ON DRUG ABUSE | 2016 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Emoji Emotion Recognition | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02971605
GET https://conductscience.org/api/trials/v1/NCT02971605/results?page=2